Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial

Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial

Background: We conducted a phase III, non-inferiority trial comparing safety and efficacy of RCP recombinant spike protein Covid-19 vaccine to BBIBP (Sinopharm). Methods: Adult Iranian population received RCP or BBIBP in a randomized, double blind and an additional non-randomized open labeled trial...

Full description

Bibliographic Details
Main Authors: Masoud Solaymani-Dodaran, Saeed Kalantari, Seyed Reza Banihashemi, Ali Es-haghi, Mojtaba Nofeli, Arash Mohazzab, Ladan Mokhberalsafa, Fariba Sadeghi, Ali Rezae Mokaram, Monireh Haji Moradi, Seyad Hossein Razaz, Maryam Taghdiri, Mohsen Lotfi, Seyed Amin Setarehdan, Safdar Masoumi, Akram Ansarifar, Saeedeh Ebrahimi, Neda Esmailzadehha, Zahra Boluki, Malihe Khoramdad, Leila Molaipour, Mohamad Hassan Rabiei, Fahimeh Bagheri Amiri, Sara Filsoof, Behrooz Bani-vaheb, Maryam Raghami Derakhshani, Sheno Bayazidi, Rezvan Golmoradizadeh, Masoumeh Shahsavan, Shiva Safari, Neda Ghahremanzadeh, Vahideh Mohseni, Saeed Erfanpoor, Mohammad Hossein Fallah Mehrabadi
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Heliyon
Subjects:
Razi-cov-pars
BBIBP
Non-inferiority design
Recombinant Covid-19 vaccine
Vaccine efficacy
Phase III clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024034017

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024034017

Similar Items